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function, particularly phosphorylation of the NR2 subunits. However little is known about the possible 
effects of NMDAR dysfunction on NRG1 signalling, which is important with regards to schizophrenia 
aetiology as numerous risk factors for the disorder can alter NMDAR functioning during early brain 
development. This review focuses on the role of the NMDA receptor subunits and NRG1 signalling in 
schizophrenia and proposes a mechanism by which a disruption to the NMDAR, particularly via altering 
the balance of NR2 subunits during early development, could influence NRG1 signalling. 
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Schizophrenia is a debilitating neurodevelopmental psychiatric disorder. Both the N-
methyl-D-aspartate receptor (NMDAR) and neuregulin1 (NRG1) are key molecules 
involved in normal brain development that have been linked to schizophrenia 
pathology and aetiology. The NR2 proteins are critical structural and functional 
subunits of the NMDAR and are developmentally and spatially regulated. Altered 
NR2 gene and protein expression has been found in human post-mortem 
schizophrenia brain tissue together with changes in NRG1 and its receptor ErbB4. 
The NR2 subunits and ErbB4 share a common anchoring domain on the postsynaptic 
density and therefore a disruption to either of these molecules may influence the 
functioning of the other. It has been shown that NRG1 signalling can affect NMDAR 
levels and function, particularly phosphorylation of the NR2 subunits. However not 
much is known about the possible effects of NMDAR dysfunction on NRG1 
signalling, which is important with regards to schizophrenia aetiology as numerous 
risk factors for the disorder can alter NMDAR functioning during early brain 
development. This review focuses on the role of the NMDA receptor subunits and 
NRG1 signalling in schizophrenia and proposes a mechanism by which a disruption to 
the NMDAR, particularly via the altering the balance of NR2 subunits during early 
development, could influence NRG1 signalling. 
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NMDA-R  N-methyl-D-aspartate receptor 
NR2A   2A subunit of the NMDA receptor 
NR2B   2B subunit of the NMDA receptor 
NRG1   Neuregulin 1   
PSD-95  Post-synaptic density protein 95 
ED   Embryonic day 
PN   Postnatal day 
PPI   Prepulse inhibition 
PCP   Phencyclidine 
TM   Transmembrane 
EGF   Epidermal growth factor 
TACE   Tumor necrosis factor-α converting enzyme 
BACE   β-site of amyloid precursor protein cleaving enzyme 
ErbB4   v-erb-a erythroblastic leukemia viral oncogene homolog 4 
SNP   Single nucleotide polymorphism 
DLPFC  Dorsolateral prefrontal cortex 
PDZ Post-synaptic density 95, Drosophila disc large tumor 
suppressor, Zonula occludens-1 
Pyk2   Proline-rich tyrosine kinase 2 








Schizophrenia is a complex mental disorder that is thought to arise from an 
interaction of genetics and environment, with its origins in early neurodevelopment. A 
considerable amount of research has focused on the role of the ionotropic glutamate 
receptor, N-methyl-D-aspartate (NMDAR), in the pathogenesis of schizophrenia, 
since the discovery several decades ago that antagonists of this receptor, such as 
phencyclidine (PCP) and ketamine, mimic symptoms of the disorder in humans and 
exacerbate symptoms in schizophrenia patients (Olney et al., 1999). Not only do these 
NMDAR antagonists induce schizophrenia-like symptoms in humans, they have also 
been shown to induce schizophrenia-like symptoms in animals, as well as neural 
circuitry changes reminiscent of schizophrenia. The ability of these NMDA receptor 
antagonists to induce this schizophrenia-like phenotype in humans and animals 
supports the concept that schizophrenia may be the result of reduced or abnormal 
functioning of the NMDAR.  
Schizophrenia is widely believed to result from disruptions early in brain 
development. The NMDAR, which plays a crucial role in brain development (du Bois 
and Huang, 2007), can be affected during early brain development by various factors 
including drug abuse during pregnancy, maternal stress or malnutrition, neonatal 
anaesthetic agents and gene mutations, which have all been associated with or 
suggested to increase the risk of developing schizophrenia (Ikonomidou et al., 2001, 
Abel et al., 2008, Shen et al., 2008).  Various animal studies have been conducted 
using perinatal NMDAR antagonist treatment to further investigate the possible 
underlying neurobiology of schizophrenia (For review see du Bois and Huang, 2007). 
Long-term behavioural effects such as enhanced locomotion (Facchinetti et al., 1993, 
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Harris et al., 2003), impairments in cognitive function as examined by spatial working 
memory, cognitive set-shifting, and other learning tests  (Sircar, 2003, Andersen and 
Pouzet, 2004, Fredriksson et al., 2004, Stefani and Moghaddam, 2005) and deficits in 
prepulse inhibition (Harris et al., 2003) are observed in adult rats and mice following 
perinatal NMDAR antagonist treatment. These behavioural changes mimic certain 
aspects of human schizophrenia and support the involvement of the glutamatergic 
system in schizophrenia-like symptoms. In addition to these behavioural changes, 
animals treated with NMDAR antagonists during the perinatal period have shown 
alterations in the brain which are similar to features of post-mortem schizophrenia 
tissue (Wilson et al., 1998, Wang et al., 2001, Sircar and Soliman, 2003, Wang et al., 
2008, du Bois et al., 2009). As well as the many proposed environmental factors that 
increase the risk of schizophrenia, various family, twin and adoption studies have 
provided strong support for genetic involvement in the pathogenesis of the disorder 
(Pulver, 2000, Maynard et al., 2001), however the inheritance appears to be in a 
complex polygenetic and non-Mendelian manner (Risch and Baron, 1984). Genetic 
linkage analyses have identified several loci that are associated with the disorder 
(Berry et al, 2003) further suggesting that no single genetic mechanism can be 
responsible for the aetiology of schizophrenia. More likely, it may be that a range of 
interacting genetic and environmental factors contribute to an increased vulnerability 
of developing the disorder (Maynard et al., 2001, Lewis and Levitt, 2002).   
Neuregulin 1 (NRG1) has been identified as one of the leading candidates for 
a schizophrenia susceptibility gene (Stefansson et al., 2002, Williams et al., 2003, 
Bakker et al., 2004, Fukui et al., 2006, Munafo et al., 2006). NRG1 signalling is 
important for early neural development as well as the regulation of neurotransmission, 
especially glutamatergic and GABAergic signalling, providing further evidence for an 
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involvement in the pathophysiology of schizophrenia (Mei and Xiong, 2008). The 
NR2 subunits of the NMDAR and the ErbB family of receptors for NRG1 share a 
common anchoring protein in the post synaptic density (Garcia et al., 2000, Lin et al., 
2004) and thus it is expected that with this structural connection a disturbance to 
either signalling pathway would produce alterations of the other. This review will 
focus on the role of NMDARs and NRG1 in schizophrenia, with a particular focus on 
the interaction between the NR2 subunits and NRG1 during early development. This 
review will present evidence supporting the reciprocal nature of the NR2/NRG1 
interaction and the consequences for schizophrenia aetiology. 
 
2. NMDA Receptors: Structure, Function and Distribution 
 
NMDARs are composed of a heterometric assembly of subunits where at least 
one obligatory NR1 subunit combines with distinct arrangements of NR2 and/or NR3 
subunits. To add to the complexity of these receptors, there are eight different splice 
variants of the gene encoding for the NR1 subunit and six other genes that encode for 
different forms of the NR2 (NR2A, NR2B, NR2C, NR2D) and NR3 (NR3A, NR3B) 
subunits, producing a multitude of different NMDAR’s (Paoletti and Neyton, 2007). 
This formation of NMDAR’s gives rise to a diverse range of functional and 
pharmacological properties (Sheng et al., 1994, Flint et al., 1997, Kristiansen et al., 
2007).  
The extracellular N-terminal domain of the NR2 subunits contains the binding 
site for glutamate, the primary activator of the NMDAR, while the NR1 subunit binds 
glycine, a co-activator. Inside the cell, the C-terminal region of the NR2 subunits is 
anchored to PDZ (Post-synaptic density 95, Drosophila disc large tumor suppressor, 
Zonula occludens-1)-containing scaffold proteins in the postsynaptic density (PSD) 
including PSD-95, synapse associated protein (SAP)102, PSD-93 and SAP97, with 
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PSD-95 being the most studied (Kornau et al., 1995, Muller et al., 1996, Niethammer 
et al., 1996, Bassand et al., 1999, Sans et al., 2000, Chen et al., 2006, Sato et al., 2008, 
Cousins et al., 2009). These proteins form the DLG (disks large homolog) subfamily 
of the membrane-associated guanylate kinases (MAGUKs), which have three PDZ 
domains, a src homology 3 (SH3) domain and a guanylate kinase domain (GUK) 
(Montgomery et al., 2004). Due to their close positioning to the postsynaptic 
membrane these proteins are involved in critical processes during synaptogenesis and 
synapse maturation including localisation, trafficking and organisation of many 
membranous and cellular proteins (Sheng and Hoogenraad, 2007, Elias et al., 2008, 
Howard et al., 2010).  
The NR2 subunits of the NMDA-R are developmentally and spatially 
regulated, providing an important level of receptor regulation. (Herin and Aizenman, 
2004, Mueller and Meador-Woodruff, 2004). Animal studies have revealed that the 
NR2B and NR2D subunits emerge early in development with NR2B and NR2D 
mRNA present prenatally in the rodent brain, as early as embryonic day 14, while the 
NR2A and NR2C mRNAs are not detectable until at or after birth (Watanabe et al., 
1992, Monyer et al., 1994, Sheng et al., 1994). Similarly NR2B protein is already 
widely and strongly expressed by birth with very little expression of NR2A and 
NR2C protein at postnatal day zero (Portera-Cailliau et al., 1996, Wenzel et al., 1997, 
Sans et al., 2000, Liu et al., 2004). The expression pattern of the PSD and SAP 
proteins mirrors that of the NR2 subunits with the SAP102 and SAP97 proteins 
present early in development and involved in synaptogenesis while PSD-95 and PSD-
93 emerge later during synapse maturation (Sans et al., 2000, Elias et al., 2008, 
Howard et al., 2010). There has been evidence to suggest that certain NR2 subunits 
preferentially associate with one or another of the DLG proteins for example, one 
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study has shown that NR2A has a slight but not complete preference for PSD-95 and 
NR2B a preference for SAP102 (Sans et al., 2000). On the other hand it has been 
found that the number of binding domains for PSD-95 on the NR2B subunit is more 
than that of the NR2A subunit and thus suggested that NR2B may be more closely 
associated to PSD-95 (Cousins et al., 2009).  
  
Throughout postnatal development, expression of NR2A mRNA and protein 
increases to a peak in all brain areas at around the third postnatal week and then a 
slight reduction in the adult rodent brain (Monyer et al., 1994, Sheng et al., 1994, 
Zhong et al., 1995, Wenzel et al., 1997, Guilarte and McGlothan, 1998, Ritter et al., 
2002). There is a pronounced increase in NR2B expression, particularly protein 
levels, during the first week in most brain regions (Monyer et al., 1994, Wenzel et al., 
1997, Ritter et al., 2002). However there appears to be conflicting results of NR2B 
expression from this point until adulthood with some studies showing cortical NR2B 
expression remains constant from early development to adulthood (Sheng et al., 1994, 
Zhong et al., 1995, Portera-Cailliau et al., 1996) while others have found a decrease in 
NR2B levels, between PN21 and adulthood (Monyer et al., 1994, Wenzel et al., 
1997). There has also been a reported decrease in NR2B mRNA levels in the 
hippocampus between PN5 to PN35 with an opposing increase occurring in NR2A 
levels (Guilarte and McGlothan, 1998, Ritter et al., 2002). The most prominent 
feature of NR2B expression during development is the confinement to forebrain areas 
in adulthood, opposing that of the NR2A subunit which is increasingly expressed in 
all brain regions throughout development (Watanabe et al., 1992, Portera-Cailliau et 
al., 1996, Wenzel et al., 1997). Forebrain areas, in particular the prefrontal cortex, 
striatum and hippocampus, are closely associated with schizophrenia pathology as the 
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neural circuits contained within and between these regions play a central role in 
eliciting the positive, negative and cognitive symptoms that are experienced by 
patients with the disorder (Heimer, 2000). Therefore this regional expression of NR2 
subunits, may play an important role in schizophrenia symptoms. 
 
The expression of NR2C mRNA and protein in the rodent brain is fairly weak 
until the third postnatal week when there is a dramatic increase in the cerebellum and 
thalamus (Monyer et al., 1994, Zhong et al., 1995, Wenzel et al., 1997). This increase 
in NR2C levels correlates with a decrease in NR2B levels in the cerebellum at this 
time suggesting a switch in the subunit expression (Monyer et al., 1994). Compared to 
the other subunits NR2D expression peaks earlier in development, around PN7, but is 
restricted to regions such as the midbrain and thalamus (Monyer et al., 1994). 
 
A similar pattern of NR2 mRNA and protein expression has been observed in 
a study of the human foetal brain, where NR2B is the predominant subunit expressed 
in all of the cortical layers as early as gestational week 8 with transient increases at 
week 11, 13 and 19 (Ritter et al., 2001). Moreover, there is a decline in NR2B mRNA 
in the human hippocampus from its peak expression during the neonatal stage of life 
to adulthood, whereas NR2A mRNA expression appears to remain consistent 
throughout the life stages (Law et al., 2003). Interestingly, the adult levels of NR2A 
and NR2B mRNA in each subregion of the hippocampus are quite similar, with the 
exception of the dentate gyrus where NR2B mRNA levels remain significantly higher 




The developmental expression of the NR1 subunit has also been considered 
with most studies indicating a slight increase from embryonic stages until the third 
postnatal week, similar to the NR2 subunits, and then a plateau effect to adulthood 
(Watanabe et al., 1992, Monyer et al., 1994, Sheng et al., 1994). However one study 
showed that the NR1 splice variants without the 5’ insert and with or without both the 
3’ inserts had a much higher expression in the cortex and hippocampus throughout 
development, while in the cerebellum, the NR1 splice variant without the 5’ insert 
dominated early in development but with the 5’ insert and without the 3’ insert was 
highest at adulthood (Zhong et al., 1995). Therefore, contrary to popular belief, there 
may also be some developmental and spatial regulation of the splice variants of the 
NR1 subunit. 
 
3. NMDA Receptor subunits and Schizophrenia 
Several studies have found alterations in the level of NR1 and NR2 mRNA 
and protein, as well as the proteins in the PSD, in schizophrenia subjects in 
comparison to control subjects (See Table 1). For example, NR1 mRNA appears to be 
decreased in the hippocampus and thalamus and increased in the occipital and anterior 
cingulate cortices (Gao et al., 2000, Ibrahim et al., 2000, Dracheva et al., 2001, 
Kristiansen et al., 2006). However these results vary in terms of the specificity of the 
probe used to detect the mRNA with some studies using pan probes while others are 
specific to certain splice variants of NR1. There are alterations in NR2 subunit mRNA 
in the prefrontal cortex, including an increase in NR2D and a reduction in NR2A and 
NR2C levels (Akbarian et al., 1996, Beneyto and Meador-woodruff, 2008). NR2B 
subunit mRNA has been found to be increased in the hippocampus (Gao et al., 2000) 
while NR2B subunit protein has been found to be selectively upregulated in the 
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superior temporal cortex (Grimwood et al., 1999). These findings show significant 
changes however there are also studies showing no changes in the same brain regions 
(See Table 1). Clinton and colleagues have found that the use of an elderly versus a 
younger cohort of samples can influence direction of change in the subunits. The PSD 
and SAP proteins appear to be particularly vulnerable to age with opposite changes in 
both the prefrontal cortex and thalamus depending on whether the cohort is elderly or 
younger aged (Clinton et al., 2003, Clinton and Meador-Woodruff, 2004, Clinton et 
al., 2006). Therefore due to the inconsistent findings, which could be attributed to 
differences in tissue cohorts and methodologies, these results must be interpreted with 
caution.     
Furthermore alterations in associated transporter and regulatory proteins of the 
NMDAR subunits has been reported in schizophrenia, particularly associated with the 
NR2B subunit (Kristiansen et al., 2010). For example, molecules in the NR2B 
trafficking complex are dysregulated in schizophrenia patients, with an increase in 
CASK and mLin7C mRNA in the prefrontal cortex and an increase in mLin7A and 
APBA mRNA and decrease in CASK and mLin7C protein in the anterior cingulate 
cortex (Kristiansen et al., 2010). 
 
TABLE 1 is about here.  
 
While human post-mortem data supports that NMDARs and their subunits are 
altered in schizophrenia, whether they be increased or decreased in brain regional 
specific manner, animal studies have and will continue to assist in unravelling the 
functional and developmental significance of those alterations in schizophrenia 
patients. There are a number of animal studies that have examined the role of a non-
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specific NMDAR blockade on behaviour and neurochemical alterations in the rodent, 
however, there is currently limited animal data available with regard to a blockade of 
the specific subunits. A small number of behavioural studies have been conducted in 
adult rodents using various NR2 antagonists, primarily NR2A and NR2B, or 
genetically modified mice. Studies have shown that Ro 25-6981, an NR2B antagonist, 
produced hyperlocomor activity (20mg/kg), disrupted prepulse inhibition (PPI) (5-
20mg/kg), an increase in a measure of anxiety-like behaviour (10mg/kg) and an 
impairment in the acquisition of fear memory (10mg/kg) in adult rats, which are well 
recognised as schizophrenia-like behaviours in the rodent (Chaperon et al., 2003, 
Mathur et al., 2009).  However there have also been reports of a lack of behavioural 
changes in rodents treated similarly (Kosowski and Liljequist, 2004, Mathur et al., 
2009). Adult rats treated with a more potent and selective NR2B antagonist, Ro 63-
1908,  displayed increased locomotor activity (10-30mg/kg) and impaired response 
inhibition (1-10mg/kg) but no disruption to PPI (1-10mg/kg) (Higgins et al., 2003). A 
recent study has shown that there are deficits in both spatial and non-spatial memory 
following a forebrain-specific deletion of NR2B, whereas hippocampal-restricted 
deletion of NR2B induces a selective working memory deficit (von Engelhardt et al., 
2008). Mice with a complete knockout of NR2B die shortly after birth and therefore 
cannot undergo behavioural analysis.  
 
On the other hand, blockade of the NR2A subunit with NVP-AAM077 has 
been reported to reduce locomotor activity (5-10mg/kg) and lack a disruption of PPI 
(5-20mg/kg) (Chaperon et al., 2003), findings supported by NR2A knockout mice 
(Spooren et al, 2004). In another study NR2A knockout mice also exhibited reduced 
anxiety and depression-like behaviour (Boyce-Rustay and Holmes, 2006).  Although 
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these studies show behavioural abnormalities that mirror schizophrenia symptoms 
with NR2B antagonists in adult animals, although they are not to the same extent as 
those observed with non-selective NMDAR antagonists. Due to the expression pattern 
of the NR2 subunits in early development and the relevance of the developmental 
neurobiology of schizophrenia, NR2 antagonist treatment may need to be further 
examined in a perinatal model in order to verify its relevance to the etiology of 
schizophrenia.  
 
Anastasio and colleagues (2009) have investigated the behavioural and 
cellular effects of perinatal NR2A and NR2B antagonism. They reported enhanced 
apoptosis following perinatal (PN7, 9 and 11) NR2A antagonist treatment (10 and 
20mg/kg PEAQX) in addition to a locomotor sensitisation effect to a phencyclidine 
(PCP) challenge, while perinatal NR2B antagonist treatment (1 or 5mg/kg ifenprodil) 
did not produce elevated apoptosis or a locomotor sensitisation to PCP (Anastasio et 
al., 2009). The NR2B antagonist (ifenprodil) used, is not as potent or specific to the 
NR2B subunit as Ro 63-1908 (Zhou et al., 1999) in which doses of up to 30mg/kg 
have been used in adult rodents. Therefore, this dose of ifenprodil may not be high 
enough to see any behavioural effects and hence there remains the possibility that 
NR2B-induced apoptosis does occur. While the apoptotic effect might be related to 
the NR2A-containing NMDAR’s, this may leave an imbalance of NR2 subunits 
(possibly via a responsive upregulation of NR2A subunits and hence a relative 
decrease in NR2B) which may cause behavioural and neurochemical abnormalities 




Changes in PSD-95 and NMDAR subunit expression have been observed 
following NMDAR antagonist treatment. One study found that acute treatment with 
the non-competitive antagonist PCP, increased the expression of membrane NR2B 
protein and decreased the level of NR2B protein in the endoplasmic reticulum on PN7 
in the frontal cortex of the rat brain (Anastasio and Johnson, 2008). This was 
suggested to be due to an increase in the trafficking of the NR2B subunit to the 
membrane. This short-term upregulation of NR2B was accompanied by an increase in 
the level of PSD-95 but not the NR2A subunit (Anastasio and Johnson, 2008). On the 
other hand subchronic treatment with PCP resulted in an elevated membrane and 
endoplasmic reticulum level of NR2A but not NR2B or PSD-95 which has been 
attributed to an increase in synthesis of NR2A protein (Anastasio and Johnson, 2008).  
Following an 8 hour NMDAR blockade an increase in the insertion of new NR2A 
subunit containing NMDA receptors has also been found in hippocampal cell cultures, 
however no change in the NR2B subunit (von Engelhardt et al., 2009). Another study 
found that NR2A mRNA was significantly increased in the striatum, cortex and 
hippocampus 4 hours following MK-801 treatment to rats on PN7 (Wilson et al., 
1998). It has been hypothesised that this imbalance of the NMDA-R subunits, 
particularly the disproportionate NR2A/NR2B ratio, after treatment with NMDAR 
antagonists causes an acceleration of the normal NMDAR development processes 
(Wilson et al., 1998). This disproportionate development of the NMDAR subunits and 
the consequent alteration in NMDAR function (Kristiansen et al., 2007) could trigger 
a cascade of modifications to other molecules such as those in the NRG1/ErbB4 






4. NRG1/ErbB4: Structure, Function and Distribution 
 
NRG1 belongs to a family of genes encoding for growth/differentiation factors 
that exert their effects on various organs, including the brain, by activating the ErbB 
tyrosine kinase receptors (Garcia et al., 2000). The NRG1 gene transcripts can be 
classed as six types and comprise over 31 different isoforms of NRG1 in total due to 
the presence of multiple promoter regions and alternative splicing of the gene 
sequence (Falls, 2003, Harrison and Law, 2006, Mei and Xiong, 2008).   
NRG1 is synthesised in a membrane-bound form, often referred to as pro-
NRG1, a precursor to the mature NRG1 signalling protein that is generated from the 
proteolytic cleavage at the extracellular transmembrane (TM) region . The release of 
the soluble extracellular portion (inclusive of the epidermal growth factor (EGF) 
domain) of NRG1 occurs in most isoforms, with the exception of type III which 
remains in contact with the cell as both the N-terminal and C-terminal of the protein 
are located intracellularly (For review see Mei and Xiong, 2008). The cleavage is 
catalysed by the proteases tumor necrosis factor-α converting enzyme (TACE), β-site 
of amyloid precursor protein cleaving enzyme (BACE) and meltrin β, and leads to the 
diffusion of mature NRG1 into the extracellular space for functional purposes (Hu et 
al., 2006, Yokozeki et al., 2007, Mei and Xiong, 2008). 
The pattern of expression of NRG1 mRNA and protein in the rodent CNS 
during development varies between the different isoforms. Type I mRNA is  
predominant during early embryogenesis whereas type II and III mRNA are not 
detected until midgestation but display a broader expression pattern in the brain 
(Meyer et al., 1997). Similarly NRG1 type I protein is expressed early in embryonic 
development with a strong distribution already present in the cortical plate, piriform 
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cortex, septum, putamen and basal telencephalon by embryonic day 17 (Pinkas-
Kramarski et al., 1994). Later in  development the distribution of NRG1 transcripts 
and protein is widespread throughout the rodent brain, mirroring that seen in the adult 
human brain (Law et al., 2004), however the expression remains in a distinct nuclei 
and cortical layer specific manner (Meyer and Birchmeier, 1994, Pinkas-Kramarski et 
al., 1994).This differential expression indicates that each isoform may have a distinct 
functional role during development (Meyer et al., 10997). ErbB4 is the predominant 
receptor for NRG1 in neurons (Bjarnadottir et al., 2007) with emerging evidence 
showing a preferential location on parvalbumin-containing GABAergic interneurons 
(Fazzari et al., 2010).  Alternative splicing of ErbB4 transcripts is known to generate 
at least four isoforms made up of different combinations of juxtamembrane (JMa and 
JMb) and intracellular regions (CYT1 and CYT2), which consequently are coupled to 
distinct signalling pathways inside the cell (For review see Mei and Xiong, 2008). 
The activation of ErbB receptors by NRG1 results in the formation of homodimers or 
heterodimers of the various receptor subtypes (ErbB1-4) and the phosphorylation of 
the intracellular kinase domain. These phosphorylated tyrosine residues are protein 
binding sites for downstream signalling molecules and enzymes that can have varying 
effects on the regulation of transcriptional and translational factors in the cell (Mei 
and Xiong, 2008).  
 
5. NRG1/ErbB4 and Schizophrenia 
Genetic linkage studies in several populations have provided strong evidence 
of NRG1 as a susceptibility gene for schizophrenia (Stefansson et al., 2002, Williams 
et al., 2003, Bakker et al., 2004, Fukui et al., 2006, Munafo et al., 2006) with multiple 
associated single nucleotide polymorphisms (SNP’s) located in the 5` and 3` regions 
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of the NRG1 gene (Mei and Xiong, 2008). Additionally, researchers have found 
altered levels of NRG1 subtypes in post-mortem brain tissue of schizophrenia patients 
(See Table 1). In particular, upregulation of NRG1 type I mRNA has been observed in 
the dorsolateral prefrontal cortex and hippocampus (Hashimoto et al., 2004, Law et 
al., 2006) and elevated NRG1 and ErbB4 protein levels have been found in the 
prefrontal cortex of schizophrenia patients (Chong et al., 2008).  Furthermore, an 
association between a SNP in the at-risk haplotype of NRG1 and altered NRG1 
transcript expression in the brain has been reported (Law et al., 2006).  
An association between the ErbB4 gene and schizophrenia has also been 
reported. The identification of single SNP’s in the non-coding, intronic region of the 
candidate gene and the increased disease risk for individuals who carry these SNP’s 
has lead researchers to investigate the possible functional consequences of these 
genetic variations (Norton et al., 2006, Silberberg et al., 2006, Law et al., 2007).  
Indeed it has been shown that certain splice-variants of ErbB4 mRNA’s are altered in 
the brains of schizophrenia patients (Law et al., 2007). CYT-1 and JM-a isoforms of 
ErbB4 are increased in the dorsolateral prefrontal cortex (DLPFC) compared to 
controls and interestingly a positive correlation has been found between the abnormal 
expression of these isoforms and the various risk SNP’s for schizophrenia (Silberberg 
et al., 2006, Law et al., 2007).  
Several genetic knockout animal studies have also highlighted the potential 
role of NRG1 in brain and behavioural abnormalities that are related to schizophrenia. 
Results have revealed that TM-domain NRG1 heterozygous mutant mice display 
hyperlocomotion, increased aggressive and exploratory behaviours, social interaction 
deficits and have impaired PPI compared to wild type mice when tested at adulthood 
(Stefansson et al., 2002, Karl et al., 2007, O'Tuathaigh et al., 2007, O'Tuathaigh et al., 
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2008). Chen and colleagues (2008) recently reported that adult mutant mice 
heterozygous for type III NRG1 also show disrupted PPI as well as impairments in 
working memory tasks, but no change in locomotor activities. These behavioural 
alterations are similar to those observed with NMDAR hypofunction in rodents and 
are also representative of schizophrenia symptomology. While these animal models 
support the possibility that genetic mutations in NRG1 could contribute to 
schizophrenia symptomology, as stated by Li and colleagues (2007), mutations in 
NRG1 genes are only likely to account for a fraction of schizophrenia cases. In other 
cases, primary dysfunction in other genes/molecules (eg glutamate) may lead to 
disrupted development of the NRG1 system and subsequently schizophrenia 
symptomology.  
 
6. NR2 and NRG1 interactions 
 
The NR2 subunits of the NMDAR and the ErbB4 receptor share a common 
anchoring region on the PDZ2 (Post synaptic density 95, Drosophila disc large tumor 
suppressor, and Zonula occludens-1) domain of PSD-95 and other molecules in the 
PSD and through this commonality it is thought that interactions occur (Garcia et al., 
2000) (Fig. 1).  
 
FIGURE 1 is about here.  
 
There have been various reports of NMDAR modulation by NRG1 signalling. 
Firstly, it has been shown that NRG1 EGF-domain heterozygous mutant mice display 
a reduction in MK-801 binding in the prefrontal cortex, suggestive of reduced 
NMDAR expression (Stefansson et al., 2002). Other studies have found that NRG1 
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stimulation in the prefrontal cortex enhances the association of ErbB4 with both PSD-
95 and the NR1 subunit in schizophrenia patients and causes a reduction in NR2A 
phosphorylation and NMDAR activation and an increase in NMDAR internalisation 
(Gu et al., 2005, Hahn et al., 2006). Highlighting a regional difference in signalling 
pathways, the disruption of NRG1-mediated ErbB4 stimulation in the hippocampus, 
also results in the loss of NMDARs (Li et al., 2007). Application of NRG1 to cultured 
hippocampal neurons does not affect the mRNA expression levels of the NR2 
subunits (Okada and Corfas, 2004) however, it has been found that NRG1 signalling 
in the hippocampus enhances phosphorylation of the NR2B subunit, concurrent with 
ErbB4 phosphorylation and the activation of Fyn and Pyk2 (proline-rich tyrosine 
kinase 2), two non-receptor tyrosine kinases thought to be involved in the downstream 
amplification of NRG1 signalling (Bjarnadottir et al., 2007). NR2B was also found to 
be hypophosphorylated in the hippocampus of TM-domain NRG1+/- mutant mice, as 
well as in ErbB4+/- mutant mice, which can lead to reduced channel opening and 
functioning of the NMDAR, but the hypophosphorylation was reversed with 
clozapine treatment (Moghaddam, 2003, Bjarnadottir et al., 2007). Interestingly, 
clozapine has also been shown to increase NR2B-containing NMDAR currents in the 
nucleus accumbens (Wittmann et al., 2005). From these findings it has been 
speculated that attenuated NRG1 signalling in the hippocampus may cause abnormal 
modulation of NMDAR function through the altered regulation of NR2B 
phosphorylation and hence, contribute to the pathophysiology of schizophrenia 
(Bjarnadottir et al., 2007). 
Adding further complications to the regional specificity of NRG1 signalling, 
NR2C mRNA expression has been found to be decreased in a population of 
schizophrenia patients with a NRG1 polymorphism in the cerebellar molecular layer 
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of the right hemisphere and vermis (Schmitt et al., 2010). Supporting this finding, the 
NRG1-β isoform has been shown to upregulate the expression of NR2C mRNA  in 
cultured cerebellar slices (Ozaki et al., 1997). Together these findings reveal the 
differential effects that NRG1 signalling has on the NMDAR subunits in the different 
brain regions, however there is still work to be done in order to further understand this 
complex signalling system. 
While it has been shown that the NRG1-ErbB4 signalling pathway can affect 
glutamatergic function, the reverse may also be true and the activity of NRG1 could 
be influenced by NMDAR functioning. The link between the NR2 subunits and the 
PSD provides support for a disruption to the NRG1/ErbB4 system following an 
NMDAR insult, as ErbB4 is also physically linked to PSD proteins. Results have 
shown that PSD-95 and ErbB4 are capable of forming a ternary complex in neurons 
which considerably increases tyrosine phosphorylation of the ErbB4 receptor and 
enhances NRG1-induced ErbB4 signalling (Huang et al., 2000). It is therefore likely 
that this regulation of the NRG1/ErbB4 pathway by PSD-95 could be affected by 
disruptions to NMDAR functioning, or more specifically the NR2 subunits, and play a 
major role in schizophrenia pathophysiology. Recent data from our laboratory has 
shown that perinatal PCP treatment can produce long-term alterations in NRG1 and 
ErbB4 protein expression (duBois, personal communication). In addition, a recent 
article by Feng and colleagues 2010 found that chronic treatment with the specific 
NMDAR antagonist MK-801 in adult rats produced an increase in NRG1 and ErbB4 
protein expression in the prefrontal cortex and hippocampus, mirroring that observed 
in schizophrenia (Feng et al., 2010). Therefore regulation of NRG1/ErbB4 signalling 
via the NMDAR is possible, however the exact mechanism of how this occurs 
remains unknown and whether there is region or subunit specificity also remains 
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elusive. Furthermore, a blockade of the NMDAR has the ability to produce functional 
deficits in GABAergic interneurons in certain cortical areas and the hippocampus (Li 
et al., 2002, Braun et al., 2007, Homayoun and Moghaddam, 2007) which similarly 
has been noted in schizophrenia pathology (Wassef et al., 2003). More specifically it 
has been shown that the loss of parvalbumin and GAD67 in cortical interneurons 
following NMDA antagonism can be attributed to the NR2A subunit (Kinney et al., 
2006). As mentioned previously these interneurons are the preferential location of 
ErbB4 receptors and so it is highly probable that alterations to NMDAR functioning 
will affect ErbB4.  
While animal studies have provided evidence for NMDAR/NRG1 
interactions, further investigation of NR2B, NR2A and NRG1 alterations and 
interactions, especially in key regions such as the prefrontal cortex and hippocampus, 
in patients with schizophrenia is necessary to be able to relate any animal study or cell 
culture findings to what is happening in the disease state.  As can be seen from Table 
1, while changes in the NR2 subunits, PSD-associated proteins, ErbB4 and NRG1 
have been reported in schizophrenia post-mortem brain tissue, there are still many 
gaps in the literature, particularly involving NRG1 and ErbB4, and many brain 
regions that have not yet been studied. From the studies to date, few have been able to 
draw any conclusions about possible NMDA/NRG1 interactions in the schizophrenia 
brain and there is a large amount of variation between the studies with regards to the 
specificity of the brain region examined, the methodologies used and the population 
and demographic data within these studies. Moreover, in addition to examining the 
mRNA and protein levels of these molecules, the signalling alterations, functional 
changes and correlations between these factors need to be examined in order to piece 







Existing knowledge has shown that both the NR2 subunits of the NMDAR 
and associated proteins in the PSD are spatially and temporally regulated throughout 
development and there is a physical link between both the NR2 subunits and ErbB4, 
and PSD proteins. Furthermore NR2 and NRG1 are functionally connected, with 
alterations to NRG1 stimulation of ErbB4 affecting NMDAR channel properties and 
subunit specific phosphorylation. However more research is required into whether this 
interaction is reciprocal, fixed, dynamic, brain region specific, isoform specific, only 
in some cell types and particularly whether it is altered in disorders such as 
schizophrenia. A further understanding of the mechanisms by which the molecules in 
these pathways are regulated would also help to gain insight into their possible role in 
schizophrenia pathophysiology.  
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Figure 1. Interaction between NR2B and NRG1 via PSD-95. 
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Both the NR2B subunit of the NMDA-R and the ErbB4-R are linked to the PDZ2 
domain of PSD-95. It has been found that alterations of NRG1 signalling can affect 
NMDA-R function and particularly that of the NR2B subunit, possibly via this 
physical link between NR2B and the NRG1 receptor, ErbB4. We propose that the 
relationship between NR2B and NRG1 is reciprocal and that a dysfunction of NR2 
subunits may influence NRG1 signalling. As both NR2B and NRG1 signalling 
pathways are involved in schizophrenia pathology, studying this interaction could 
provide further knowledge of the mechanism of their involvement in schizophrenia 
and possible interventions. 
Abbreviations:- NMDA-R: N-methyl-D-aspartate receptor, NR2B: subunit 2B of the 
NMDA-R, NR1: subunit 1 of the NMDA-R, NRG1: Neuregulin1, ErbB4: v-erb-a 
erythroblastic leukemia viral oncogene homolog 4, PSD-95: post-synaptic density 
protein 95, PDZ2: Post-synaptic density 95, Drosophila disc large tumor suppressor, 
Zonula occludens-1, Fyn: Proto-oncogene tyrosine-protein kinase Fyn. 
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